On Wednesday, Shares of Rovi Corporation (NASDAQ:ROVI), gained 0.78% to $16.73.
Rovi Corporation (ROVI), declared the expansion of Rovi’s entertainment discovery patent license agreement with Shaw Communications Inc., a major Canadian cable and satellite service provider serving 2.6 million video customers across Canada. The deal expands the scope of usage under Shaw’s existing long-term license agreement to Rovi’s intellectual property.
Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide. The company offers interactive program guides (IPGs), an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and plan video programming for viewing and recording.
Shares of Synchrony Financial (NYSE:SYF), declined -0.85% to $30.43, during its last trading session.
Synchrony Financial (SYF) plans to report its fourth quarter 2015 results before the market opens on Friday, January 22, 2016.
During the current month, Wall Street analysts gave the rating about the company shares whether it is time to BUY, SELL or HOLD the shares. “13” analyst said that BUY the stock and Strong BUY signal was issued by “7” analysts. Sell rating was given by “0” analysts. Hold signal was recommended by “1” analysts. Underperform rating was given by “0” analysts.
Synchrony Financial operates as a consumer financial services company in the United States. The company offers private label credit cards, dual cards, and small and medium-sized business credit products; and promotional financing for consumer purchases, such as private label credit cards and installment loans.
Finally, Geron Corporation (NASDAQ:GERN), ended its last trade with -2.65% loss, and closed at $4.95.
On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%.
Geron Corp.’s stock raised by 3.81% to close Friday’s session at USD 4.91. The company’s shares fluctuated in the range of USD 4.68 and USD 4.95. A total of 15.07 million shares exchanged hands, which was much above its 50-day and 52-week daily average volumes of 2.91 million shares and 3.02 million shares, respectively. Over the last three days Geron Corp.’s shares have advanced 8.63% and in the past one week the shares have moved up 13.92%. Furthermore, over the last three months the stock has gained 36.77% and in the past six months the shares have picked up 22.44%. The company has returned 22.14% in the last half year, on a compounded total return basis. The stock is trading at a price to book (MRQ) ratio of 5.06, which compares to a historical PB ratio near to 3.91. Additionally, the stock is trading at a price to sales (TTM) ratio of 20.60.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
